Habib Dable

Advisor

Habib Dable is a Raven Advisor, focusing on advising and supporting newcos, portfolio companies and executives within Raven. Habib brings to Raven nearly three decades of experience as a strategic leader in Big Pharma and emerging Biotech. Prior to joining Raven, Habib spent five years as President and CEO at Acceleron Pharma. In this role, he propelled the company to the next stage of growth and increased shareholder value by altering the course of this formerly research-based company to prioritize innovation, speed to commercialization, and culture transformation. While at Acceleron he successfully launched the company’s first blockbuster asset — REBLOZYL® — and brought in the company’s lead drug — Sotatercept — prior to Acceleron’s eventual sale to Merck in 2021. Prior to Acceleron, Habib held various leadership roles at Bayer AG during his ~22-year tenure with the company. As President, U.S. Pharmaceuticals at Bayer, he directed a multi-billion-dollar portfolio of products across multiple therapeutic areas (cardiovascular disease, hematology, neurology, oncology, and women’s health). Prior to that, he held roles as Executive Vice President, Global Head Specialty Medicine and Vice President, Ophthalmology/​Global Launch Team Head, EYLEA®. Habib received his BBA in Marketing & Finance and his MBA in International Business from University of New Brunswick. He completed the Executive Program at Stanford University, Graduate School of Business, as well as the Executive to Leader Institute at Korn/​Ferry International. Habib has earned his Director Professionalism® Certificate from the National Association of Corporate Directors.